Cargando…

Probing rate of YMDD motif mutant in lamivudine treatment of Iranian patients with chronic hepatitis B virus infection

BACKGROUND: Lamivudine is an analog nucleoside used for the treatment of chronic hepatitis B virus (CHV) infection. Studies showed that prolonged therapy could induce lamivudine resistance hepatitis B virus (HBV) variants (YMDD motif). In this study, the rate of YMDD motif mutants is determined in l...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ghandehari, Freshte, Pourazar, Abasali, Zadeh, Mehrnaz Shanehsaz, Tajedin, Nahid
Formato:	Texto
Lenguaje:	English
Publicado:	Medknow Publications 2011
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3082713/ https://www.ncbi.nlm.nih.gov/pubmed/21572712 http://dx.doi.org/10.4103/0973-6247.75982

Ejemplares similares

YMDD motif mutation after lamivudine therapy
por: Jazayeri, Seyed Mohammad, et al.
Publicado: (2011)

Detection of YMDD Motif Mutants by Oligonucleotide Chips in Lamivudine-Untreated Patients with Chronic Hepatitis B Virus Infection
por: Heo, Jeong, et al.
Publicado: (2004)

Inflammation Pharmacological Reaction and YMDD Mutational Patterns in Lamivudine Therapeutics Hepatitis B Virus
por: Liu, Hongcan, et al.
Publicado: (2021)

Viral quasispecies of hepatitis B virus in patients with YMDD mutation and lamivudine resistance may not predict the efficacy of lamivudine/adefovir rescue therapy
por: Wang, Changtai, et al.
Publicado: (2019)

YMDD Motif Mutation Profile Among Patients Receiving Liver Transplant Due to Hepatitis B Virus Infection With Long Term Lamivudine/Immunoglobulin Therapy
por: Rahimi, Rahim, et al.
Publicado: (2015)

The Clinical Value of Oxymatrine in Preventing Lamivudine Induced YMDD Mutation: A Meta-Analysis
por: He, Min, et al.
Publicado: (2015)

Novel mutation in YMDD motif and direct neighbourhood in a child with chronic HBV-infection and clinical lamivudine and adefovir resistance - a scholarly case
por: Schildgen, Verena, et al.
Publicado: (2010)

Natural YMDD motif mutations in treatment naïve patients with chronic hepatitis B in Huzhou of eastern China
por: Qian, Fuchu, et al.
Publicado: (2016)

The Naturally Occurring YMDD Mutation among Patients Chronically Infected HBV and Untreated with Lamivudine: A Systematic Review and Meta-Analysis
por: Tan, Youwen, et al.
Publicado: (2012)

Compensatory variances of drug-induced hepatitis B virus YMDD mutations
por: Cai, Ying, et al.
Publicado: (2016)

Detection of mixed populations of wild-type and YMDD hepatitis B variants by pyrosequencing in acutely and chronically infected patients
por: Mello, Francisco C A, et al.
Publicado: (2012)

Long-Term Outcomes and Dynamics of Mutants Associated with Lamivudine-Adefovir Rescue Therapy in Patients with Lamivudine-Resistant Chronic Hepatitis B
por: Kim, Jihyun, et al.
Publicado: (2015)

Detection of rtN236T mutation associated with adefovir dipivoxil resistance in Hepatitis B infected patients with YMDD mutations in Tehran
por: Monavari, Seyed Hamidreza, et al.
Publicado: (2013)

Lamivudine Resistance and Precore Variants in Iranian Patients With Chronic Hepatitis B: Correlation With Virological and Clinical Features
por: Poortahmasebi, Vahdat, et al.
Publicado: (2015)

Meta-analysis: Adefovir dipivoxil in combination with lamivudine in patients with lamivudine-resistant hepatitis B virus
por: Chen, En-Qiang, et al.
Publicado: (2009)

Lamivudine/Adefovir Treatment Increases the Rate of Spontaneous Mutation of Hepatitis B Virus in Patients
por: Pereira-Gómez, Marianoel, et al.
Publicado: (2016)

Lamivudine treatment for severe acute HBV hepatitis
por: Lisotti, Andrea, et al.
Publicado: (2008)

Lamivudine plus adefovir combination therapy for lamivudine resistance in hepatitis-B-related hepatocellular carcinoma patients
por: Kim, Jeong Han, et al.
Publicado: (2013)

Treatment of Hepatitis B Virus-Associated Membranous Nephropathy: Lamivudine Era versus Post-Lamivudine Era
por: Moon, Ju-Young, et al.
Publicado: (2012)

Comparison of tenofovir plus lamivudine versus tenofovir monotherapy in patients with lamivudine-resistant chronic hepatitis B
por: Park, Chan Ho, et al.
Publicado: (2016)

Design and psychometrics cultural competence questionnaire for health promotion of Iranian nurses
por: Gol, Mehdi Khanbabayi, et al.
Publicado: (2019)

In silico and in vitro studies of cytotoxic activity of different peptides derived from vesicular stomatitis virus G protein
por: Ghandehari, Fereshte, et al.
Publicado: (2015)

Lamivudine Therapy for Korean Children with Chronic Hepatitis B
por: Koh, Hong, et al.
Publicado: (2007)

Adefovir Dipivoxil Alone or in Combination with Ongoing Lamivudine in Patients with Decompensated Liver Disease and Lamivudine-resistant Hepatitis B Virus
por: Kim, Kang Mo, et al.
Publicado: (2005)

Lamivudine plus adefovir is a good option for chronic hepatitis B patients with viral relapse after cessation of lamivudine treatment
por: Wang, Zhao, et al.
Publicado: (2011)

Efficacy of Lamivudine or Entecavir on Acute Exacerbation of Chronic Hepatitis B
por: Kanda, Tatsuo, et al.
Publicado: (2011)

Entecavir and lamivudine therapy for severe acute chronic hepatitis B
por: LIU, CHANGHONG, et al.
Publicado: (2013)

High Dose of Lamivudine and Resistance in Patients with Chronic Hepatitis B
por: Wani, Hamid Ullah, et al.
Publicado: (2014)

Evaluation of Anticancer Activity of Fruit and Leave Extracts from Virus Infected and Healthy Cultivars of Vitis vinifera
por: Esfahanian, Zahra, et al.
Publicado: (2013)

Treatment with lamivudine versus lamivudine and thymosin alpha-1 for e antigen-positive chronic hepatitis B patients: a meta-analysis
por: Zhang, Yuan-Yuan, et al.
Publicado: (2009)

Evaluating the efficacy of switching from lamivudine plus adefovir to tenofovir disoproxil fumarate monotherapy in lamivudine-resistant stable hepatitis B patients
por: Lee, Heon Ju, et al.
Publicado: (2018)

Design of a standard Iranian protocol of Intravenous thrombolysis with tissue plasminogen activator: A national project
por: Ghandehari, Kavian
Publicado: (2013)

Combination therapy of lamivudine and adefovir in Japanese patients with chronic hepatitis B
por: Shakado, Satoshi, et al.
Publicado: (2008)

Update on rescue therapies in patients with lamivudine-resistant chronic hepatitis B
por: Chao, Daniel C, et al.
Publicado: (2013)

Lamivudine Therapy Exacerbates Bilirubinemia in Patients Underlying Severely Advanced Hepatitis
por: Choi, Young Hee, et al.
Publicado: (2017)

Lamivudine therapy for chronic hepatitis B in children: a meta-analysis
por: Luo, Aoran, et al.
Publicado: (2019)

Successful treatment of infantile hepatitis B with lamivudine: A case report
por: Zhang, Yu-Ting, et al.
Publicado: (2021)

Lamivudine plus adefovir combination therapy versus entecavir monotherapy for lamivudine-resistant chronic hepatitis B: a systematic review and meta-analysis
por: Sheng, Yun-Jian, et al.
Publicado: (2011)

Long-term outcomes of two rescue therapies in lamivudine-refractory patients with chronic hepatitis B: combined lamivudine and adefovir, and 1-mg entecavir
por: Ze, EunYoung, et al.
Publicado: (2014)

Emergence of the rtA181T/sW172* mutant increased the risk of hepatoma occurrence in patients with lamivudine-resistant chronic hepatitis B
por: Yeh, Chau-Ting, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_f2qajmrgud09fi0lk0le44mnib